Fresh analysis indicates that patients who come off blockbuster slimming jabs like Wegovy and Mounjaro may regain shed pounds much more quickly than those who end traditional diet and exercise plans.
Published data in a leading health publication points out that while overweight people frequently drop about a fifth of their total mass while on the medication, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"People purchasing these treatments need to be cognizant of the risk of quick rebound weight gain when the treatment ends," stated researcher Dr. Susan Jebb.
That rate of regain implies a reversion to original weight in about a year and a half.
Comparing Approaches
The research, which looked at dozens of studies involving over 9,000 of participants, compared the results of these new drugs with conventional dieting.
Scientists emphasize that people who lose weight through dieting generally have a slower creep back—perhaps 100 grams monthly—after stopping.
Explaining the Rapid Regain
Experts propose the way of the jabs accounts for the amplified regain.
The injections mimic a natural hormone called glucagon-like peptide-1, which controls hunger.
"Artificially providing GLP-1 levels far above than the body's typical production might result in the system to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement means appetite is no longer kept in check, making overeating a significant risk."
A Lifelong Condition?
Health authorities suggest the injections for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
Professionals say that, given the likelihood of weight regain, the therapy should be considered life-long.
This perspective is echoed by drug manufacturers, who note that the results "emphasize the chronic character of obesity," comparing it to managing conditions like hypertension.
Patient Accounts
Individuals who have discontinued the jabs explain a powerful resurgence of cravings.
"It was like a switch activating and I was suddenly extremely hungry," recalled an individual.
This difficulty is exacerbated if users have not developed permanent dietary or behavioural modifications during therapy.
Growing Interest
Figures indicate that millions of adults in the UK have used weight-loss jabs in the past year, with demand remaining high.
- Use is greater among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic fix and long-term success hinges on ongoing lifestyle support.
